-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to new statistics, there are 129 million diabetic patients in China, accounting for about 10% of China's total population
.
With the increase of diabetics, hypoglycemic drugs have attracted much attention from the market
.
It is understood that, to this day, insulin is still one of the effective treatment methods for diabetic patients, and it will continue to be improved and optimized
.
For insulin, patients may welcome good news, that is, the sixth batch of national drug procurement is about to open, and insulin may be imported into the country
.
According to the "National Drug Centralized Procurement Document (Insulin Special) (GY-YD2021-3)" previously issued by the National Organization Drug Joint Procurement Office, the time for the application information for this centralized drug procurement is November 26
.
This centralized procurement is the sixth batch of national procurement, and is aimed at the diabetes treatment drug insulin
.
According to public information, this is the first time that insulin has entered the national procurement, and it is also the first time that a biological drug has entered the national procurement
.
According to the industry, the national sourcing means price cuts.
For more than 100 million diabetic patients in China, insulin will bid farewell to the "sweet burden" in the near future
.
According to the announcement, the types of centralized procurement include mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues, totaling 6 purchasing groups
.
Some analysts pointed out that the 81 varieties collected this time, specifically, there are 43 second-generation insulins, accounting for more than 50%, and 38 third-generation insulins, accounting for nearly 50%.
The majority of the varieties are pre-mixed.
The human insulin product group (there are 18 varieties), there are only two product groups of basal insulin and premixed insulin analogues, both of which have only 12 varieties
.
From an analysis point of view, the second-generation insulin and the third-generation insulin may compete more intensely in this centralized procurement
.
In addition, an analyst in the pharmaceutical industry said that due to the large base of diabetes patients and insulin is an important drug for diabetes treatment, which involves people’s livelihood issues, the country has an incentive to reduce the cost of medication.
It is expected that the price competition for centralized procurement will be fierce.
.
The announcement showed that the quotation unit of each purchasing group of this centralized insulin procurement is represented by the 3ml:300 unit (refill) specification, and the highest effective declaration price is given for different varieties
.
Among them, the highest effective declaration price for mealtime human insulin, basal human insulin, and premixed human insulin is 50 yuan/piece, mealtime insulin analogues and premixed insulin analogues are 72 yuan/piece, and basal insulin analogues are 132 yuan/piece.
.
It is understood that diabetes is mainly divided into type 1 diabetes and type 2 diabetes.
Type 1 diabetes relies on insulin, and patients with type 2 diabetes must also receive insulin treatment under certain conditions
.
Regarding the importance of insulin, some people in the industry said that many drugs now work through insulin in the body
.
Many drugs can prolong the use of insulin, but none of them can drive insulin off, because we have only one hypoglycemic hormone in our body
.
Therefore, to this day, insulin is still one of the effective treatments for diabetes
.
The industry generally believes that the centralized procurement of insulin may affect the market share of foreign companies in China
.
It is understood that in the domestic market, insulin companies are relatively concentrated
.
Statistics show that last year, the sales of terminal insulin and similar drugs in public medical institutions in China were close to 27 billion yuan, of which three foreign companies, namely Novo Nordisk, Sanofi, and Eli Lilly, had a combined market share of over 70%
.
Among domestic insulin companies, Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories occupy an important position.
In 2020, Ganli Pharmaceutical's insulin market share will exceed 10%
.
The industry said that with the development of centralized insulin procurement, these three pharmaceutical companies may benefit first
.
.
With the increase of diabetics, hypoglycemic drugs have attracted much attention from the market
.
It is understood that, to this day, insulin is still one of the effective treatment methods for diabetic patients, and it will continue to be improved and optimized
.
For insulin, patients may welcome good news, that is, the sixth batch of national drug procurement is about to open, and insulin may be imported into the country
.
According to the "National Drug Centralized Procurement Document (Insulin Special) (GY-YD2021-3)" previously issued by the National Organization Drug Joint Procurement Office, the time for the application information for this centralized drug procurement is November 26
.
This centralized procurement is the sixth batch of national procurement, and is aimed at the diabetes treatment drug insulin
.
According to public information, this is the first time that insulin has entered the national procurement, and it is also the first time that a biological drug has entered the national procurement
.
According to the industry, the national sourcing means price cuts.
For more than 100 million diabetic patients in China, insulin will bid farewell to the "sweet burden" in the near future
.
According to the announcement, the types of centralized procurement include mealtime human insulin, basal human insulin, premixed human insulin, mealtime insulin analogues, basal insulin analogues, and premixed insulin analogues, totaling 6 purchasing groups
.
Some analysts pointed out that the 81 varieties collected this time, specifically, there are 43 second-generation insulins, accounting for more than 50%, and 38 third-generation insulins, accounting for nearly 50%.
The majority of the varieties are pre-mixed.
The human insulin product group (there are 18 varieties), there are only two product groups of basal insulin and premixed insulin analogues, both of which have only 12 varieties
.
From an analysis point of view, the second-generation insulin and the third-generation insulin may compete more intensely in this centralized procurement
.
In addition, an analyst in the pharmaceutical industry said that due to the large base of diabetes patients and insulin is an important drug for diabetes treatment, which involves people’s livelihood issues, the country has an incentive to reduce the cost of medication.
It is expected that the price competition for centralized procurement will be fierce.
.
The announcement showed that the quotation unit of each purchasing group of this centralized insulin procurement is represented by the 3ml:300 unit (refill) specification, and the highest effective declaration price is given for different varieties
.
Among them, the highest effective declaration price for mealtime human insulin, basal human insulin, and premixed human insulin is 50 yuan/piece, mealtime insulin analogues and premixed insulin analogues are 72 yuan/piece, and basal insulin analogues are 132 yuan/piece.
.
It is understood that diabetes is mainly divided into type 1 diabetes and type 2 diabetes.
Type 1 diabetes relies on insulin, and patients with type 2 diabetes must also receive insulin treatment under certain conditions
.
Regarding the importance of insulin, some people in the industry said that many drugs now work through insulin in the body
.
Many drugs can prolong the use of insulin, but none of them can drive insulin off, because we have only one hypoglycemic hormone in our body
.
Therefore, to this day, insulin is still one of the effective treatments for diabetes
.
The industry generally believes that the centralized procurement of insulin may affect the market share of foreign companies in China
.
It is understood that in the domestic market, insulin companies are relatively concentrated
.
Statistics show that last year, the sales of terminal insulin and similar drugs in public medical institutions in China were close to 27 billion yuan, of which three foreign companies, namely Novo Nordisk, Sanofi, and Eli Lilly, had a combined market share of over 70%
.
Among domestic insulin companies, Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories occupy an important position.
In 2020, Ganli Pharmaceutical's insulin market share will exceed 10%
.
The industry said that with the development of centralized insulin procurement, these three pharmaceutical companies may benefit first
.
